{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T08:24:31Z","timestamp":1787300671437,"version":"build-2736575974"},"reference-count":54,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"abstract":"\n Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease, and early detection remains challenging because conventional biomarkers lack sensitivity. MicroRNAs (miRNAs) have emerged as promising non-invasive biomarkers, but evidence remains inconsistent. This study systematically evaluated dysregulated miRNAs in DKD and their associations with clinical parameters across albuminuria stages. PubMed, Scopus, and Embase were searched for studies assessing miRNA expression in DKD. Standardised mean differences (SMDs) were pooled using random-effects models, and risk of bias was assessed using the Newcastle\u2013Ottawa Scale. The SMD of urinary miRNA124 in normoalbuminuria was 2.04 (95% CI: 1.16\u20132.92,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200977.2%,\n p<\/jats:italic>\n \u2009\u2264\u20090.00001), microalbuminuria 7.76 (95% CI: 5.67\u20139.84,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200978.1%,\n p<\/jats:italic>\n \u2009\u2264\u20090.00001), and macroalbuminuria 13.04 (95% CI: 10.94\u201315.13,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200940.8%,\n p<\/jats:italic>\n \u2009<\u20090.00001). Urinary and circulating miRNA21 showed progressive upregulation across normoalbuminuria, microalbuminuria, and macroalbuminuria with SMDs of 3.34 (95% CI: \u22120.56 to 7.24,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200995.9%,\n p<\/jats:italic>\n \u2009=\u20090.0933) and 0.50 (95% CI: \u22120.36 to 1.36,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200989.7%,\n p<\/jats:italic>\n \u2009=\u20090.2520); 4.02 (95% CI: 2.69\u20135.36,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200980.0%,\n p<\/jats:italic>\n \u2009<\u20090.0001) and 1.78 (95% CI: 0.00\u20133.56,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200996.7%,\n p<\/jats:italic>\n \u2009=\u20090.0499); and 4.61 (95% CI: 0.18\u20139.03,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200997.8%,\n p<\/jats:italic>\n \u2009=\u20090.0413) and 4.77 (95% CI: \u22121.29 to 10.82,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200998.4%,\n p<\/jats:italic>\n \u2009=\u20090.1230), respectively. Circulating miRNA126 was consistently downregulated in normoalbuminuria, microalbuminuria, and macroalbuminuria with SMDs \u22120.85 (95% CI: \u22121.87 to 0.18,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200995.0%,\n p<\/jats:italic>\n \u2009=\u20090.1044), \u22121.59 (95% CI: \u22122.67 to \u22120.52,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200993.0%,\n p<\/jats:italic>\n \u2009=\u20090.0035), and \u22121.87 (95% CI: \u22124.67 to 0.93,\n I<\/jats:italic>\n 2<\/jats:sup>\n \u2009=\u200998.1%,\n p<\/jats:italic>\n \u2009=\u20090.1901). Urinary miRNA192 was downregulated, whereas circulating miRNA192 showed inconsistent expression. Correlation analyses demonstrated positive associations between urinary miRNA34a and UACR (\n r<\/jats:italic>\n \u2009=\u20090.39) and HbA1c (\n r<\/jats:italic>\n \u2009=\u20090.20), while circulating miRNA21 (\n r<\/jats:italic>\n \u2009=\u2009\u22120.37) and miRNA192 (\n r<\/jats:italic>\n \u2009=\u2009\u22120.26) were inversely associated with albuminuria. Overall, urinary miRNA124, miRNA21, and miRNA34a, together with circulating miRNA126 and miRNA192, show promise as biomarkers of DKD progression, although prospective validation studies are required.\n <\/jats:p>","DOI":"10.1177\/10815589261473283","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:12:51Z","timestamp":1784884371000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating and urinary microRNAs in diabetic kidney disease: Stage and sample-specific signatures with biomarker potential \u2013 A systematic review and exploratory meta-analysis"],"prefix":"10.1177","author":[{"given":"Gangireddy","family":"Venkatratna Bharat","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Department of General Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MohanRam","family":"Murugan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Department of General Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ria","family":"Murugesan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Ayyasamy","sequence":"additional","affiliation":[{"name":"Division of Medical Research, Faculty of Medicine and Health Sciences, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumitha","family":"Haridoss","sequence":"additional","affiliation":[{"name":"Division of Medical Research, Faculty of Medicine and Health Sciences, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2231-0213","authenticated-orcid":false,"given":"Janardanan Subramonia","family":"Kumar","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Department of General Medicine, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Chen Y Lee K Ni Z et al. Diabetic kidney disease: challenges advances and opportunities. Kidney Dis 2020; 6: 215\u2013225. https:\/\/doi.org\/10.1159\/000506634","DOI":"10.1159\/000506634"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Faselis C Katsimardou A Imprialos K et al. Microvascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol 2020; 18: 117\u2013124. https:\/\/doi.org\/10.2174\/1570161117666190502103733","DOI":"10.2174\/1570161117666190502103733"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Hoogeveen EK. The epidemiology of diabetic kidney disease. Kidney Dial 2022; 2: 433\u2013442. https:\/\/doi.org\/10.3390\/kidneydial2030038","DOI":"10.3390\/kidneydial2030038"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Cantarin MPM McCauley J. Epidemiology of end-stage renal disease and kidney transplantation. In: Ramirez C McCauley J (eds) Contemporary kidney transplantation. Organ and tissue transplantation. Springer Cham 2018. https:\/\/doi.org\/10.1007\/978-3-319-19617-6_24","DOI":"10.1007\/978-3-319-19617-6_24"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Campion CG Sanchez-Ferras O Batchu SN. Potential role of serum and urinary biomarkers in diagnosis and prognosis of diabetic nephropathy. Can J Kidney Health Dis 2017; 4: 2054358117705371. https:\/\/doi.org\/10.1177\/2054358117705371","DOI":"10.1177\/2054358117705371"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Shao Y Ren H Lv C et al. Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 2017; 55: 130\u2013138. https:\/\/doi.org\/10.1007\/s12020-016-1069-4","DOI":"10.1007\/s12020-016-1069-4"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Ma X Lu C Lv C et al The expression of miR-192 and its significance in diabetic nephropathy patients with different urine albumin creatinine ratio. J Diabetes Res 2016; 2016: 1\u20136. https:\/\/doi.org\/10.1155\/2016\/6789402","DOI":"10.1155\/2016\/6789402"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Maranduca MA Clim A Pinzariu AC et al. Role of arterial hypertension and angiotensin II in chronic kidney disease (Review). Exp Ther Med 2023; 25: 153. https:\/\/doi.org\/10.3892\/etm.2023.11852","DOI":"10.3892\/etm.2023.11852"},{"key":"e_1_3_2_10_2","first-page":"298","article-title":"Consequences of advanced glycation end products accumulation in chronic kidney disease and clinical usefulness of their assessment using a non-invasive technique \u2013 skin autofluorescence","volume":"6","author":"Oleniuc M","year":"2011","unstructured":"Oleniuc M, Secara I, Onofriescu M, et al. Consequences of advanced glycation end products accumulation in chronic kidney disease and clinical usefulness of their assessment using a non-invasive technique \u2013 skin autofluorescence. Maedica 2011; 6: 298\u2013307.","journal-title":"Maedica"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Rani P Koulmane Laxminarayana SL Swaminathan SM et al. TGF-\u03b2: elusive target in diabetic kidney disease. Ren Fail 2025; 47: 2483990. https:\/\/doi.org\/10.1080\/0886022X.2025.2483990","DOI":"10.1080\/0886022X.2025.2483990"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Kato M Natarajan R. MicroRNAs in diabetic nephropathy: functions biomarkers and therapeutic targets. Ann N Y Acad Sci 2015; 1353: 72\u201388. https:\/\/doi.org\/10.1111\/nyas.12758","DOI":"10.1111\/nyas.12758"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Wu H Kong L Zhou S et al. The role of MicroRNAs in diabetic nephropathy. J Diabetes Res 2014; 2014: 1\u201312. https:\/\/doi.org\/10.1155\/2014\/920134","DOI":"10.1155\/2014\/920134"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Dykes IM Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genom Proteom Bioinform 2017; 15: 177\u2013186. https:\/\/doi.org\/10.1016\/j.gpb.2016.12.005","DOI":"10.1016\/j.gpb.2016.12.005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Kato M. Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease. Kidney Res Clin Pract 2018; 37: 197\u2013209. https:\/\/doi.org\/10.23876\/j.krcp.2018.37.3.197","DOI":"10.23876\/j.krcp.2018.37.3.197"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Nascimento LRD Domingueti CP. MicroRNAs: new biomarkers and promising therapeutic targets for diabetic kidney disease. Braz J Nephrol 2019; 41: 412\u2013422. https:\/\/doi.org\/10.1590\/2175-8239-jbn-2018-0165","DOI":"10.1590\/2175-8239-jbn-2018-0165"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Cirkovic A Stanisavljevic D Milin-Lazovic J et al. 2021. Preeclamptic women have disrupted placental microRNA expression at the time of preeclampsia diagnosis: meta-analysis. Front Bioeng Biotechnol 2021; 9: 782845. https:\/\/doi.org\/10.3389\/fbioe.2021.782845","DOI":"10.3389\/fbioe.2021.782845"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Mahtal N Lenoir O Tinel C et al. MicroRNAs in kidney injury and disease. Nat Rev Nephrol 2022; 18: 643\u2013662. https:\/\/doi.org\/10.1038\/s41581-022-00608-6","DOI":"10.1038\/s41581-022-00608-6"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Mishima Y Tomari Y. Codon usage and 3\u2032 UTR length determine maternal mRNA stability in zebrafish. Mol Cell 2016; 61: 874\u2013885. https:\/\/doi.org\/10.1016\/j.molcel.2016.02.027","DOI":"10.1016\/j.molcel.2016.02.027"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Mishra DD Sahoo B Maurya PK et al. Therapeutic potential of urine exosomes derived from rats with diabetic kidney disease. Front Endocrinol 2023; 14: 1157194. https:\/\/doi.org\/10.3389\/fendo.2023.1157194","DOI":"10.3389\/fendo.2023.1157194"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Uil M Hau CM Ahdi M et al. Cellular origin and microRNA profiles of circulating extracellular vesicles in different stages of diabetic nephropathy. Clin Kidney J 2021; 14: 358\u2013365. https:\/\/doi.org\/10.1093\/ckj\/sfz145","DOI":"10.1093\/ckj\/sfz145"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Wang N Zhang C. Recent advances in the management of diabetic kidney disease: slowing progression. Int J Mol Sci 2024; 25: 3086. https:\/\/doi.org\/10.3390\/ijms25063086","DOI":"10.3390\/ijms25063086"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Baker MA Davis SJ Liu P et al. Tissue-specific MicroRNA expression patterns in four types of kidney disease. J Am Soc Nephrol 2017; 28: 2985\u20132992. https:\/\/doi.org\/10.1681\/ASN.2016121280","DOI":"10.1681\/ASN.2016121280"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Donderski R Szczepanek J Naruszewicz N et al. Analysis of profibrogenic microRNAs (miRNAs) expression in urine and serum of chronic kidney disease (CKD) stage 1\u20134 patients and their relationship with proteinuria and kidney function. Int Urol Nephrol 2022; 54: 937\u2013947. https:\/\/doi.org\/10.1007\/s11255-021-02928-1","DOI":"10.1007\/s11255-021-02928-1"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Jiang L Li L Zhang K et al. A systematic review and meta-analysis of microRNAs in the diagnosis of early diabetic kidney disease. Front Endocrinol 2025; 16: 1432652. https:\/\/doi.org\/10.3389\/fendo.2025.1432652","DOI":"10.3389\/fendo.2025.1432652"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"Shi Y Liu Z Lin Q et al. MiRNAs and cancer: key link in diagnosis and therapy. Genes 2021; 12: 1289. https:\/\/doi.org\/10.3390\/genes12081289","DOI":"10.3390\/genes12081289"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Zhou S-S Jin J-P Wang J-Q et al. miRNAS in cardiovascular diseases: potential biomarkers therapeutic targets and challenges. Acta Pharmacol Sin 2018; 39: 1073\u20131084. https:\/\/doi.org\/10.1038\/aps.2018.30","DOI":"10.1038\/aps.2018.30"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Ouzzani M Hammady H Fedorowicz Z et al. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 2016; 5: 210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Yang X Liu S Zhang R et al. Microribonucleic acid-192 as a specific biomarker for the early diagnosis of diabetic kidney disease. J Diabetes Investig 2018; 9: 602\u2013609. https:\/\/doi.org\/10.1111\/jdi.12753","DOI":"10.1111\/jdi.12753"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","unstructured":"Al-Kafaji G Al-Muhtaresh H. Expression of microRNA-377 and microRNA-192 and their potential as blood-based biomarkers for early detection of type 2 diabetic nephropathy. Mol Med Rep 2018; 18(1): 1171\u20131180. https:\/\/doi.org\/10.3892\/mmr.2018.9040","DOI":"10.3892\/mmr.2018.9040"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","unstructured":"Chien H-Y Chen C-Y Chiu Y-H et al. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci 2016; 13: 457\u2013465. https:\/\/doi.org\/10.7150\/ijms.15548","DOI":"10.7150\/ijms.15548"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","unstructured":"Nossier AI Shehata NI Morsy SM et al. Determination of certain urinary microRNAs as promising biomarkers in diabetic nephropathy patients using gold nanoparticles. Anal Biochem 2020; 609: 113967. https:\/\/doi.org\/10.1016\/j.ab.2020.113967","DOI":"10.1016\/j.ab.2020.113967"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Al-Kafaji G Al-Mahroos G Al-Muhtaresh HA et al. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: a potential blood-based biomarker. Exp Ther Med 2016; 12: 815\u2013822. https:\/\/doi.org\/10.3892\/etm.2016.3395","DOI":"10.3892\/etm.2016.3395"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","unstructured":"Akhbari M Khalili M Shahrabi-Farahani M et al. Expression level of circulating cell free miR-155 gene in serum of patients with diabetic nephropathy. Clin Lab 2019; 65(8). https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190209","DOI":"10.7754\/Clin.Lab.2019.190209"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","unstructured":"Eissa S Matboli M Aboushahba R et al. Urinary exosomal microRNA panel unravels novel biomarkers for diagnosis of type 2 diabetic kidney disease. J Diabetes Complicat 2016; 30: 1585\u20131592. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.07.012","DOI":"10.1016\/j.jdiacomp.2016.07.012"},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","unstructured":"Milas O Gadalean F Vlad A et al. Deregulated profiles of urinary micrornas may explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus. J Investig Med 2018; 66: 747\u2013754. https:\/\/doi.org\/10.1136\/jim-2017-000556","DOI":"10.1136\/jim-2017-000556"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Petrica L Milas O Vlad M et al. Interleukins and Mirnas intervene in the early stages of diabetic kidney disease in type 2 diabetes mellitus patients. Biomark Med 2019; 13: 1577\u20131588. https:\/\/doi.org\/10.2217\/bmm-2019-0124","DOI":"10.2217\/bmm-2019-0124"},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","unstructured":"Petrica L Hogea E Gadalean F et al. Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients. Int J Med Sci 2021; 18: 2093\u20132101. https:\/\/doi.org\/10.7150\/ijms.56551","DOI":"10.7150\/ijms.56551"},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","unstructured":"Akp\u0131nar K Aslan D Fenk\u00e7i SM et al. miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy. Diagnosis 2022; 9: 499\u2013507. https:\/\/doi.org\/10.1515\/dx-2022-0036","DOI":"10.1515\/dx-2022-0036"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Jia Y Guan M Zheng Z et al. miRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. J Diabetes Res 2016; 2016: 1\u201310. https:\/\/doi.org\/10.1155\/2016\/7932765","DOI":"10.1155\/2016\/7932765"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Tayel SI Saleh AA El-Hefnawy SM et al. Simultaneous assessment of MicroRNAs 126 and 192 in diabetic nephropathy patients and the relation of these MicroRNAs with urinary albumin. Curr Mol Med 2020; 20: 361\u2013371. https:\/\/doi.org\/10.2174\/1566524019666191019103918","DOI":"10.2174\/1566524019666191019103918"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Xing C Lu Y Liu G et al. The expression of miR-377-3p in patients with DKD and the regulatory mechanism of miR-377-3p on the inflammatory response of HK-2 cells through TGF-\u03b2. Diabetes Metab Syndr Obes 2024; 17: 903\u2013911. https:\/\/doi.org\/10.2147\/DMSO.S449791","DOI":"10.2147\/DMSO.S449791"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Xing C Huo L Tang H et al. The predictive value of miR-377 and phospholipase A2 in the early diagnosis of diabetic kidney disease and their relationship with inflammatory factors. Immunobiology 2024; 229: 152792. https:\/\/doi.org\/10.1016\/j.imbio.2024.152792","DOI":"10.1016\/j.imbio.2024.152792"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","unstructured":"Sun H Chen T Li X et al. The relevance of the non-invasive biomarkers lncRNA GAS5\/miR-21 ceRNA regulatory network in the early identification of diabetes and diabetic nephropathy. Diabetol Metab Syndr 2023; 15: 197. https:\/\/doi.org\/10.1186\/s13098-023-01179-7","DOI":"10.1186\/s13098-023-01179-7"},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","unstructured":"Wang J Wang G Liang Y et al. Expression profiling and clinical significance of plasma MicroRNAs in diabetic nephropathy. J Diabetes Res 2019; 2019: 1\u201312. https:\/\/doi.org\/10.1155\/2019\/5204394","DOI":"10.1155\/2019\/5204394"},{"key":"e_1_3_2_46_2","doi-asserted-by":"crossref","unstructured":"Abdelaty TAEF Morsy EY El-Sayed ET et al. Plasma microRNA-192 expression as a potential biomarker of diabetic kidney disease in patients with type 2 diabetes mellitus. Clin Diabetol 2020; 9: 454\u2013460. https:\/\/doi.org\/10.5603\/DK.2020.0045","DOI":"10.5603\/DK.2020.0045"},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","unstructured":"Li D Lu Z Jia J et al. Changes in microRNAs associated with podocytic adhesion damage under mechanical stress. J Renin Angiotensin Aldosterone Syst 2013; 14: 97\u2013102. https:\/\/doi.org\/10.1177\/1470320312460071","DOI":"10.1177\/1470320312460071"},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","unstructured":"Park S Moon S Lee K et al. Urinary and blood MicroRNA-126 and -770 are potential noninvasive biomarker candidates for diabetic nephropathy: a meta-analysis. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 2018; 46: 1331\u20131340. https:\/\/doi.org\/10.1159\/000489148","DOI":"10.1159\/000489148"},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","unstructured":"Putta S Lanting L Sun G et al. Inhibiting MicroRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012; 23: 458\u2013469. https:\/\/doi.org\/10.1681\/ASN.2011050485","DOI":"10.1681\/ASN.2011050485"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","unstructured":"Zhang L He S Guo S et al. Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1. J Diabetes Complicat 2014; 28: 259\u2013264. https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.01.002","DOI":"10.1016\/j.jdiacomp.2014.01.002"},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","unstructured":"Yamakuchi M Ferlito M Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421\u201313426. https:\/\/doi.org\/10.1073\/pnas.0801613105","DOI":"10.1073\/pnas.0801613105"},{"key":"e_1_3_2_53_2","doi-asserted-by":"crossref","unstructured":"Verzola D Gandolfo MT Ferrario F et al. Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 2007; 72: 1262\u20131272. https:\/\/doi.org\/10.1038\/sj.ki.5002531","DOI":"10.1038\/sj.ki.5002531"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","unstructured":"Castro RE Ferreira DMS Afonso MB et al. miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 2013; 58: 119\u2013125. https:\/\/doi.org\/10.1016\/j.jhep.2012.08.008","DOI":"10.1016\/j.jhep.2012.08.008"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","unstructured":"Liang Y Liu H Zhu J et al. Inhibition of p53\/miR-34a\/SIRT1 axis ameliorates podocyte injury in diabetic nephropathy. Biochem Biophys Res Commun 2021; 559: 48\u201355. https:\/\/doi.org\/10.1016\/j.bbrc.2021.04.025","DOI":"10.1016\/j.bbrc.2021.04.025"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261473283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589261473283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589261473283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T07:49:26Z","timestamp":1787298566000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589261473283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":54,"alternative-id":["10.1177\/10815589261473283"],"URL":"https:\/\/doi.org\/10.1177\/10815589261473283","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"10815589261473283"}}